By VETTAPHARMA reporter – Derek Roche: Takeda Pharmaceutical Company provided an update on a U.S. jury verdict in antitrust litigation concerning Amitiza and announced a related revision to its fiscal year 2025 financial results. The company said the verdict and ensuing legal developments have prompted an adjustment to previously reported FY2025 figures and will affect near‑term reported results.
The statement, issued May 22, 2026, outlined Takeda’s immediate actions following the jury decision, including planned legal steps and internal accounting measures to reflect the outcome. Management indicated the company is evaluating appeals and other procedural options while implementing the required financial reporting revisions under applicable accounting standards.
Takeda described the financial impact as material to FY2025 results and said it will reflect the change in its next public reporting cycle. The company noted the revision affects consolidated results for the period and that additional details, including the specific accounting charge and its effect on net income and adjusted metrics, will be disclosed in forthcoming filings and investor communications.
Operationally, Takeda said it will continue to supply and support patients and healthcare providers during the legal process, and that commercial availability of Amitiza remains subject to ongoing litigation outcomes and regulatory obligations. The company emphasized continuity of care and its commitment to managing supply and access while legal and financial matters are resolved.
Strategically, Takeda framed the update as a discrete legal and accounting event that does not alter its broader R&D and commercial priorities. The company signalled it will engage with stakeholders, including investors and regulators, to explain the revision and its implications for near‑term performance and longer‑term planning.
